Modality
Multispecific
MOA
STINGag
Target
KRASG12C
Pathway
Wnt
MesoBCCRB
Development Pipeline
Preclinical
~Apr 2012
→ ~Jul 2013
Phase 1
~Oct 2013
→ ~Jan 2015
Phase 2
~Apr 2015
→ ~Jul 2016
Phase 3
~Oct 2016
→ ~Jan 2018
NDA/BLA
~Apr 2018
→ ~Jul 2019
Approved
Oct 2019
→ Jun 2027
ApprovedCurrent
NCT04622333
1,997 pts·BCC
2019-10→2027-06·Terminated
1,997 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-06-261.2y awayPh3 Readout· BCC
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Approved
Termina…
Catalysts
Ph3 Readout
2027-06-26 · 1.2y away
BCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04622333 | Approved | BCC | Terminated | 1997 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| RHH-5389 | Roche | Preclinical | RET | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 |